PreComb is continuously expanding its clinical network to increase patient reach and scientific exchange. If you are interested of being engaged to further advance personalized medicine capabilities, please contact us at email@example.com.
PreComb offers the unique opportunity, together with its clinical partners, to test exploratory drugs and drug combinations on tumor twins derived from primary human tumor tissue to test for clinical efficacy.
For clinical investigators
PreComb is continuously expanding its clinical network to increase patient reach and scientific exchange. If you are interested of being engaged to further advance personalized medicine capabilities, please contact us.
Our key clinical collaborations include:
University Hospital Zürich, Switzerland
PreComb collaborates with Prof. Dr. Chantal Pauli and Prof. Dr. med. Holger Moch of the Institute of Pathology and Molecular Pathology at the University Hospital Zürich (USZ) to develop novel prognostic models for pancreatic cancer and sarcoma patients.
Hopp Children's Cancer Center (KiTZ) of DKFZ, University Heidelberg and University Hospital Heidelberg, Germany
PreComb collaborates with Prof. Dr. Olaf Witt and PD Dr. Ina Oehme to clinically validate the PreComb’s fully automated drug profiling solution (3DTwin™ technology) in pediatric patients. The “Hopp Children’s Cancer Center Heidelberg” (KiTZ) is a joint institution of the German Cancer Research Center (DKFZ), the Heidelberg University and the Heidelberg University Hospital.
Medical University Innsbruck, Austria
PreComb collaborates with Dr. med. Arno Amann and Prof. Dr. med. Dominik Wolf of the Department of Internal Medicine V at the Medical University Innsbruck to explore the potential of patient-derived microtumors to predict the response of immune-oncological drugs.